Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer
Status:
Active, not recruiting
Trial end date:
2022-05-31
Target enrollment:
Participant gender:
Summary
The POLE mutations represent high somatic mutation loads in patients with colorectal cancer,
especially in those with MMR proficient or MSS, therefore, tumors harbouring POLE mutations
might be susceptible to immune checkpoint blockade.
Based on these reasons, the investigators planned a phase II study of durvalumab monotherapy
in patients with previously treated, metastatic, MMR deficient (MSI-H) or POLE mutated
colorectal cancer.